Alison Gulbis π·πβπΌ retweeted
A major update from ASTCT! New consensus grading criteria refine CRS and ICANS assessments and address emerging toxicities following immune effector cell therapy, supporting standardized toxicity evaluation across clinical trials and practice. ow.ly/Wsig5103RX0
Alison Gulbis π·πβπΌ retweeted
ICYMI.
We canβt let ourselves become numb to children dying from diseases that have been long eradicated in our countryβ¦
π
A child in New York has died after contracting measles, Gov. Kathy Hochul said in a statement. It is the state's first measles-related death in 30 years. cnn.com/2026/11/02/health/neβ¦
New from Healio and ASTCT
The treatment landscape for classical Hodgkin lymphoma continues to evolve with the introduction of novel agents and changing transplantation strategies. In this Healio Q&A, Sairah Ahmed, MD, discusses ASTCTβs updated clinical practice recommendations, including the role of autologous transplantation, integration of brentuximab vedotin and checkpoint inhibitors, maintenance approaches, and current considerations for allogeneic transplantation.
Explore how these evidence-based recommendations are helping clinicians navigate the modern management of relapsed or refractory classical Hodgkin lymphoma.
Read more: ow.ly/6vYJ5101nGp
Alison Gulbis π·πβπΌ retweeted
A reminder that we donβt vaccinate just to protect ourselves. We also vaccinate for:
- Immunocompromised people
- Older adults
- Infants too young to be vaccinated
We vaccinate for people we love, people we will never meet, people whose protection depends in part on us.
Alison Gulbis π·πβπΌ retweeted
HEADS UP! ππ΄ This week a LUNAR ECLIPSE will be visible across the United States Thursday evening into early Friday morning! 96% of the Moonβs visible disk will slip into Earthβs shadow. So close to totality that most of it will have a red tint while only a thin bright sliver remains.
Peak Viewing Times
Eastern: 12:13 AM (Friday)
Central: 11:13 PM (Thursday)
Mountain: 10:13 PM (Thursday)
Pacific: 9:13 PM (Thursday)
Only wild card of course will be your local weather, hope for the best! This should be one of the best lunar eclipses visible from the Unites States until the next total lunar eclipse in December 2028. Enjoy and get those cameras ready!
- Matt Devitt Weather
Alison Gulbis π·πβπΌ retweeted
Phase I/II Trial of Evomela for ASCT for MM. Evomela 225 mg/mΒ² improves MRDβnegative CR rates and shows a high probability of longer PFS vs MEL200 #mmsm #bmtsm @UTMDAnderson @DQBMD @BloodPortfolio ashpublications.org/bloodadvβ¦
The #Tandem27 APP Track is seeking speakers for the 2027 meetings in Orlando! The planing committee is especially seeking proposals that are evidence-based, highlight current data, and illustrate advances in the field of transplantation and cellular therapy. Visit the link below to learn more and apply by Sunday, July 12.
Apply now: ow.ly/Cpkq50ZieAC
Alison Gulbis π·πβπΌ retweeted
Replying to @ASHPOfficial
@ASHPofficial At ASHP Futures 2026, Dr. Ted Morton reflects on 30+ years in pharmacy precepting after receiving the ASHP Foundation Preceptor Awardβ& what it really takes to shape the next generation of pharmacists.
π₯ Watch now: pharmacypracticenews.com/a/7β¦ #ASHP
Alison Gulbis π·πβπΌ retweeted
No cervical cancer deaths in women who had HPV vaccine
ZERO
Its an amazing vaccine that PREVENTS CANCER
RFK Jr hates it. Doesn't want you to get it.
Would rather you or your daughter got cancer than a vaccine
Strange man
Cervical cancer deaths fall to zero in young women given vaccine bbc.in/4ovjOLq
Dr. Zahra Mahmoudjafari, PharmD, BCOP, FHOPA, MBA, is the first author of the article βFrom Vision to Viability: Developing Infrastructure for Cell and Gene Therapy Programs.β She shares in this Q&A background on how this research came about, findings that particularly surprised her, and how these findings are guiding current and future initiatives.
ow.ly/45XQ50Z6X0I
Alison Gulbis π·πβπΌ retweeted
The @us_fda has issued a 'safe to proceed' to a clinical trial for a new application for a novel CAR T cell therapy for some lymphoma patients.
Dr. Sattva Neelapu shares more. spr.ly/6015BBLBuD
Where does cord blood transplantation make the greatest impact in non-malignant disease? Join the ASTCT Cord Blood SIG to explore its role in Severe Combined Immunodeficiency (SCID) and Krabbe disease, with a focus on early intervention, patient selection, transplant strategy and long-term outcomes. Register: ow.ly/184350YWlUL
Alison Gulbis π·πβπΌ retweeted
Most of you will never have had:
Measles
Mumps
Rubella
Tetanus
Diphtheria
Polio
And none of you will ever have had Smallpox
Why?
Because vaccines work
Alison Gulbis π·πβπΌ retweeted
π¨ JUST NOW: The entirety of US Congress ERUPTS in a standing ovation when King Charles III drops this line
βMagna Carta is cited in at least 160 Supreme Court cases in 1789, not least as the foundation of the principle that executive power is subject to CHECKS AND BALANCES."
It's almost time for the Q2 2026 edition of the HOPA Virtual Practice Management series - and registration is now open. Our latest webinar has 1.25 ACPEs on offer, and itβs completely free for HOPA members! Find out more and register at bit.ly/3QBbOf7
No matter where you practice, you donβt have to solve complex bispecific antibody questions alone. Presenting HOPA's Pharmacy Peer Network - providing timely, one-on-one access to bispecific antibody therapy subject matter experts. Find out more: bit.ly/3OQdgd5
HOPA is proud to be one of the organizations that signed this joint statement regarding the recent ACIP Charter changes
Today, ASHP and partnering pharmacy organizations expressed concerns about the recently revised charter for the Centers for Disease Control and Preventionβs Advisory Committee on Immunization Practices. Our joint statement recommends steps to restore public confidence in the nation's vaccine advisory panel. hubs.ly/Q04cyxrL0
Adenovirus remains an important infectious complication following alloHCT, particularly in the setting of evolving GVHD prophylaxis strategies. This journal club will review a contemporary study evaluating the incidence, timing, and clinical outcomes of adenovirus infection in patients receiving PTCy-based prophylaxis. Register now: ow.ly/fgia50YMT1W



























